Skip to main content

Table 1 Disease demographics and management data

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Parameter N (%)
Age (median) 62.6 years
Gender (Female/Male) 97 (43.0%)/129 (57.0%)
Histological Grade  
1–2 170 (75.2%)
3-4 46 (20.4%)
Obstruction Yes/No 30 (13.2%)/179 (79.2%)
Perforation Yes/No 9 (4.0%)/201 (89.0%)
Primary Site Left/Right 165 (73.0%)/60 (26.6%)
Rectum 71 (31.0%)
TNM stage at biopsy  
I-III versus IV 83 (36.8%)/137 (60.6%)
Median Follow Up 73.6 months
Deaths 175 (77.4%)
Line of therapy at Cetuximab administration  
1st line 38 (16.8%)
2nd line 108 (47.8%)
3rd line and beyond 80 (35.4%)
Type of therapy at Cetuximab administration  
Irinotecan-based 153 (48.7%)
Oxaliplatin-based 84 (26.7%)
Both irinotecan and oxaliplatin 29 (9.2%)
Only fluoropyrimidine 6 (1.9%)
Single-agent Cetuximab 42 (13.4%)
Objective Response to Cetuximab  
All lines of therapy  
Complete Respone (CR) 2 (0.9%)
Partial Response (PR) 55 (24.4%)
ORR (CR+PR) 57 (25.3%)
Stable disease (SD) 66 (29.3%)
Progressive disease (PD) 70 (31.1%)
ORR by line of Cetuximab therapy  
1st line 17 (44.7%)
2nd line 23 (21.5%)
3rd line 14 (22.9%)